Exclusive Research Collaboration, License and Option Agreement Sample Contracts

Exclusive Research Collaboration, License and Option Agreement Between LogicBio Therapeutics, Inc. and CANbridge Care Pharma Hong Kong Limited

Exclusive Research Collaboration, License and Option Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

• Contract Type
  Exclusive Research Collaboration, License and Option Agreement
• Filed
  August 9th, 2021
• Company
  LogicBio Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

This Exclusive Research Collaboration, License and Option Agreement (this “Agreement”) is entered into as of April 26, 2021 (the “Effective Date”) by and between CANbridge Care Pharma Hong Kong Limited, a Hong Kong limited liability company, having its registered address at FLAT/RM A 12/F, ZJ300, 300 Lockhart Road, Wan Chai, Hong Kong (“CANbridge”) and LogicBio Therapeutics, Inc., a Delaware corporation having its principal place of business at 65 Hayden Ave., Floor 2, Lexington, MA 02421, United States (“LogicBio”). CANbridge and LogicBio are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”